| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 18 | — | 17.8x | Bottom tier | |
Growth | 75 | 19.2% | 7.1% | Top tier | |
Quality | 29 | -24.8% | 4.5% | Bottom tier | |
Safety | 47 | — | 2.6x | Around median | |
Capital Return | 35 | — | 2.12% | Bottom tier | |
Momentum | 96 | 319.9% | 2.9% | Top tier | |
Sentiment | 38 | 7 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Twist Bioscience develops a semiconductor chip-based DNA manufacturing platform that converts digital designs into DNA, proteins, and physical characterization data for customers in drug discovery, diagnostics, academic research, and industrial applications. The company generates revenue through two main groups: DNA manufacturing and protein solutions, and next-generation sequencing applications, NGS; its platform also enables iterative design-build-test cycles for AI-enabled drug discovery programs.
In Q3 fiscal 2026, Twist reported record revenue of $118.4 million, up 23% year over year, and gross profit of $62.5 million at a gross margin of 52.8%. However, net loss was $35.1 million, or $0.56 per share, while adjusted EBITDA loss was $11.3 million. This period marked the fourteenth consecutive quarter of sequential revenue growth.
Q3 fiscal 2026 revenue was split between $56.6 million from DNA manufacturing and protein solutions, up 39% year over year, and $61.8 million from NGS applications, up 12%. By end market, therapeutics revenue was $40.4 million, up 49%; diagnostics was $43.8 million, up 15%; academic and government was $15.5 million, up 32%; global partners was $12.9 million; and industrial and applications was $5.7 million.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is "Buy," with an average price target of $104.67, within a wide range of $89 to $120. The average target is approximately 33% below the 52-week high of $155.44, while no positive price-to-earnings ratio is available because of continuing losses; therefore, the valuation depends heavily on achieving triple-digit growth in AI orders and reaching adjusted EBITDA breakeven. The positive consensus must be weighed against the wide 52-week range of $23.30 to $155.44 and the continuing net loss.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
Twist generates revenue primarily from DNA manufacturing and protein solutions and next-generation sequencing application products, NGS. In Q3 fiscal 2026, the first group generated $56.6 million, while NGS applications generated approximately $61.8 million. Use cases include drug discovery, diagnostics, academic research, and industrial applications, and the platform converts digital sequences into DNA, proteins, and physical characterization data.
Twist customers use AI to design thousands or millions of sequences, and these programs then rely on the company to manufacture DNA, express proteins, and test their properties. Orders related to AI-enabled drug discovery were $25 million in fiscal 2025, and management expects triple-digit growth in fiscal 2026 with the potential to repeat it in fiscal 2027. On August 19, 2026, Anthropic selected Twist to test AI-designed proteins, increasing interest in this driver.
Twist has not achieved profitability under generally accepted accounting principles, reporting a net loss of $35.1 million in Q3 fiscal 2026 and a loss per share of $0.56. Adjusted EBITDA loss was $11.3 million in the same quarter, with operating expenses of $98.7 million that included approximately $2 million in employee transition costs. Management is targeting adjusted EBITDA breakeven in Q4 fiscal 2026, supported by an expected reduction of more than $5 million in operating expenses compared with the previous quarter.
Twist relies on a semiconductor chip-based DNA manufacturing platform and offers genes, pooled and assembled DNA, protein expression, data characterization, and NGS products. In July 2026, the company commercially launched its complex genes offering after an early-access phase that included more than 1,800 genes across more than 100 orders, with the vast majority completed within 12 days. NGS drivers include tumor-informed molecular residual disease tests, along with ligase and polymerase enzymes developed by the company for use in genomic workflows.
The primary financial risk is continuing losses, as net loss for the twelve-month period within fiscal 2026 was approximately $136.7 million, while no positive price-to-earnings ratio is available. There is also concentration risk within NGS because the ten largest customers represented approximately 48% of the group's revenue in Q3 fiscal 2026. The company also faces competition from suppliers such as GenScript and potential discounting pressure, while the wide 52-week range of $23.30 to $155.44 reflects high sensitivity to changes in growth and profitability expectations.
Twist raised its fiscal 2026 revenue guidance to $456–457 million, representing year-over-year growth of approximately 21%. It expects revenue of $123–124 million in Q4 fiscal 2026, representing year-over-year growth of approximately 25% at the midpoint, with sequential growth in the DNA and protein and NGS groups. It also expects a gross margin above 52% for fiscal 2026 and adjusted EBITDA breakeven in Q4 fiscal 2026.
